Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant CAPOX plus surgery after SEMS or stoma for left-sided obstructive colorectal cancer
jRCTs021230067Phase 2Recruiting
- Start
- Mar 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine and oxaliplatin in colorectal cancer (CRC). Primary endpoint: 3-year disease-free survival rate. Started Mar 2024; status: recruiting.
02
Drugs
capecitabineoxaliplatin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCTs021230067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs021230067.